Organization
Regeneron Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Regeneron Pharmaceuticals, Inc.
... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the 29th Annual Piper ...
... diversified portfolio in case any one particular sector gives up the ghost." Regeneron CEO on Novartis competition Recent competition from Novartis AG hasn't phased Dr. ...
... TARRYTOWN - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data analyses from the ...
... a new trial and vacated permanent injunction in U.S. Praluent®patent case Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the third quarter of 2017 ...
... Regeneron Pharmaceuticals is about to release a television ad campaign for one of ...
... Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced new data analyses from the Praluent® ...
... transform the treatment of moderate to severe atopic dermatitis. As Dupixent (dupilumab; Regeneron/Sanofi) gains traction, older, more toxic immunosuppressant options will lose ground as treating ...
... TARRYTOWN, N.Y. - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 1 clinical ...
... Kura Oncology Inc. (NASDAQ: KURA), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), and Seattle Genetics Inc. (NASDAQ: SGEN). Biotech companies are engaged ...
... definition page 8; (6) 2016 Business EPS was EUR5.68; (7) Collaboration with Regeneron.Investor Relations: (+) 33 1 53 77 45 45 - E-mail: IR@sanofi.com - ...
... immunotherapy AR101. And last month, the California biotech announced a deal with Regeneron to test its allergy medication in combination with Sanofi/Regeneron’s Dupixent (dupilumab). Its ...
... Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN) today announced that data from two Phase 1 clinical trials of ...
... evaluate cemiplimab (also known as REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), in combination with Inovio's INO-5401 T cell activating immunotherapy encoding ...
... first ever global Day for Doing Good, a company-wide day of service. Regeneron colleagues are participating in more than 225 community service projects that will ...
... France and Tarrytown, NY - October 31, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 investigational study evaluating dupilumab in ...
... Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today celebrated the company's first ever globalDay for Doing Good, ...
... Limerick, Ireland - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), one of the fastest-growing companies in the global biotechnology industry, ...
... one employer in its annual survey of the biotech and pharmaceutical industry. Regeneron has been ranked first for five of the past seven years, with ...
... Q3. Additionally, four out of five respondents report recent contact with a Sanofi/Regeneron representative, and trial rates among those who have seen a Sanofi/Regeneron sales ...
... Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced thatSciencemagazine has once again ranked the company as ...
... may also be biased towards certain decisions, Equilar said. Equilar found that Regeneron Pharmaceuticals paid its directors the most in 2016 at nearly $2.1 million. ...
... TARRYTOWN, N.Y. and PARIS - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from a Phase 2 ...
... Requirements by Configuring an eTMF System Jason Weinstein, Business Lead for eTMF, REGENERON Case Study: Hear AbbVie's Business System Operation Support (BSOS) - Experience Implementing ...
... develop a cure for peanut allergies Aimmune Therapeutics is teaming up with Regeneron Pharmaceuticals in hopes of developing a cure for peanut allergies. Aimmune, based ...
... TARRYTOWN, N.Y. - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤